AKBA News Alert Akebia Therapeutics Inc. (AKBA) 11.33 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 3:34 AM

Akebia Therapeutics Inc. (AKBA) 11.33 $AKBA

Akebia to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Thu Dec 04, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11,2014 at 1:00 p.m. Eastern Time. The conference will take place at Crowne Plaza Times Square Manhattan in New York City.
AKBA: 11.33 (+0.25)

Akebia Therapeutics President and Chief Executive Officer Establishes Stock Purchase Plan
Business Wire - Mon Nov 17, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), announced today that John P. Butler, President and Chief Executive Officer of Akebia, has established a personal stock purchasing plan to acquire shares of the company's common stock. The purchasing plan complies with Section 10b5-1 of the Securities Exchange Act of 1934, as amended, which enables securities holders to adopt pre-arranged stock purchasing plans for the acquisition of predetermined amounts of securities on a non-discretionary basis.
AKBA: 11.33 (+0.25)

Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CLUB: 6.22 (+0.01), HYGS: 12.54 (+0.20), KNDI: 12.45 (-0.40), MCEP: 6.50 (-0.07), HYG.TO: 14.78 (+0.60), RPRX: 8.74 (+0.26), SHLD: 32.30 (+0.15), PAA.TO: 11.34 (+0.02), PAAS: 9.76 (-0.07), REXX: 5.18 (+0.03), AKBA: 11.33 (+0.25), GCBC: 29.69 (+0.03), ASEI: 47.24 (-1.33), MTEX: 28.10 (-1.00), PLNR: 7.29 (+0.29)

Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting
Business Wire - Tue Nov 11, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the AKB-6548 development program will be presented in two poster sessions at the upcoming American Society of Nephrology (ASN) Kidney Week 2014 annual meeting in Philadelphia, PA from November 11-16, 2014.
AKBA: 11.33 (+0.25)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST

UCP: 10.92 (+0.14), JRJC: 7.62 (-0.31), NAVB: 1.49 (+0.19), SANW: 3.75 (-0.20), PLPM: 1.68 (+0.04), RYN: 26.83 (-0.37), INFU: 2.74 (-0.03), LIOX: 5.50 (-0.07), DY: 31.46 (-0.66), MTZ: 19.18 (-0.96), CGIX: 6.30 (unch), MUX: 1.11 (-0.05), OREX: 5.74 (-0.02), URRE: 1.98 (+0.09), ACHN: 13.28 (-0.11), REN: 1.10 (-0.11), MPO: 1.07 (-0.23), AKBA: 11.33 (+0.25), TRX: 0.74 (-0.06), PLNR: 7.29 (+0.29)

Akebia misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:20AM CST

AKBA: 11.33 (+0.25)

Akebia Announces Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2014.
AKBA: 11.33 (+0.25)

Akebia to Participate in Upcoming Investor Conferences
Business Wire - Fri Oct 31, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in two upcoming investor conferences:
AKBA: 11.33 (+0.25)

Akebia getting roughed up
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 2:55PM CDT

AKBA: 11.33 (+0.25)

Akebia renal anemia drug successful in Phase 2
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 6:13AM CDT

AKBA: 11.33 (+0.25)

Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
Business Wire - Mon Oct 27, 5:30AM CDT
--Company Plans to Initiate Global Phase 3 Registration Studies in 2015
AKBA: 11.33 (+0.25)

Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis
Business Wire - Thu Sep 25, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that the first patient has been dosed in a Phase 2 clinical study of AKB-6548 in patients with anemia related to chronic kidney disease (CKD) who are undergoing dialysis. AKB-6548 is being developed as a once-daily, oral therapy with best-in-class potential for the treatment of anemia related to CKD.
AKBA: 11.33 (+0.25)

Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:57AM CDT
Concert Pharmaceuticals, Inc. (CNCE) was a big mover last session, as the company saw its shares rise nearly 26% on the day.
LCI: 43.58 (-0.46), AKBA: 11.33 (+0.25), CNCE: 11.22 (+0.03), HPTX: 21.89 (+0.02)

Others Overlooked Akebia Therapeutics (AKBA), Should You Buy It Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:45AM CDT
Akebia Therapeutics has been witnessing a positive trend in its current year estimates and possess a favorable Zacks Rank #2(Buy)
AKBA: 11.33 (+0.25)

Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors
Business Wire - Mon Sep 15, 6:15AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that Ronald C. Renaud, Jr., former President, Chief Executive Officer and Director of Idenix Pharmaceuticals, Inc., has been appointed to Akebia's Board of Directors.
AKBA: 11.33 (+0.25), IDIX: 24.50 (+0.05)

Akebia Therapeutics, Inc. (NASDAQ: AKBA) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Thu Sep 11, 9:06AM CDT
What:
AKBA: 11.33 (+0.25), NDAQ: 46.11 (-0.86)

Can the Uptrend Continue for Akebia (AKBA)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:33AM CDT
Can the Uptrend Continue for Akebia (AKBA)?
AKBA: 11.33 (+0.25)

Akebia Announces Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 6:00AM CDT
---Strengthens Management Team and Board-
AKBA: 11.33 (+0.25)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Goodyear's Strategic Shift: New Leadership, New Path

Big Shoes, Bigger Expectations Who's steering the Goodyear ship now that Mark Stewart's out the door? Roger Wood's the name, interim CEO is the game. Don't fret too much—the board's hustling to nail down a permanent top dog. But this isn't a musical chairs game; it's a full-on strategic shift. Goodyear's forming committees, juggling ideas, and ripping through their...

Leatt Gears Up for Q3 Results Conference Call

A good heads-up, folks, isn't just about keeping helmets snug—it’s about knowing when to cash in, especially when Leatt Corporation's got their Q3 results ready to drop. November 12 is the big day, so circle that on your calendars. They're rolling out the numbers before the market even gets its coffee, possibly nudging the ticker, OTCQB:LEAT, in a ripple you’ll want...

KT&G Launches Heated Tobacco in Kazakhstan's Market

KT&G Lights Up Kazakhstan In a bold move, KT&G is laying down the gauntlet in Kazakhstan's tobacco market, introducing its cutting-edge heated tobacco gizmo and a handful of sleek FAIIM sticks. Launching this October, these aren't just any devices—they're the FLEX locals have been waiting for, rebranded from South Korea's lil AIBLE and AIIM but made to fit right in with...

Laboratoires Pierre Fabre and XtalPi Unite for AI-Driven Drug Hunt

An Unexpected Turn in the Drug Discovery Arena It's not every day that you see a historic French pharma powerhouse and a cutting-edge Chinese tech firm join forces. On one side, we've got Laboratoires Pierre Fabre, steeped in the history and nitty-gritty of clinical drug development. On the other, we’ve got XtalPi Holdings Limited (2228.HK), bringing their high-tech AI...

Paul Taubman Takes Helm at Cold Spring Harbor Lab

Paul Taubman Steers the Ship at CSHL Here's the buzz coming out of Cold Spring Harbor Lab: they're handing the reins over to Paul Taubman. It's like swapping captains in the middle of the ocean—big shoes need to stay afloat. This place isn't just the playground for science nerds; it's a powerhouse in biomedical research. Now, we've got Taubman, a fella who's been...

TalentNeuron and CodeSignal Team Up: Impact on Workforce

Skills Intelligence Takes Center Stage There's a fresh breeze blowing through the workforce planning domain, thanks to the newly expanded partnership between TalentNeuron and CodeSignal. They've strapped together their expertise to craft what's now touted as the most comprehensive skills intelligence available to organizations. A claim big enough to make us stop,...

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Zabalafin Hydrogel: Promise in Treating Atopic Dermatitis

Pioneering a New Path in Dermatology Treatment In the world of dermatology, finding a topical solution that tackles the full spectrum of atopic dermatitis (AD) is as rare as hens' teeth. But here's a twist—in a recent research paper gracing the Journal of Drugs in Dermatology, Alphyn Biologics sheds light on their unique contender, Zabalafin Hydrogel. This ain't your...

Children's Institute Gala Raises $4M: A Night to Remember

Breaking Records and Honoring Legends You know, sometimes there's more to the world than stocks and ticker tapes. Over in Los Angeles, the Children's Institute pulled off a real spectacle with their Annual Cape & Gown Gala, drawing in more than 600 folks and raking in a whopping $4 million. That's right, four million clams in one evening—a record-breaker for them. When...

Elevest's Record Fund 69: Real Estate lures IRA Investors

The Evolution of Retirement Investing Retirement accounts finding their way into real estate? Now that’s what I call a twist in the tired tale of saving for golden years. It's like investors finally woke up from the dull thud of traditional stocks and bonds, realizing there might just be something more lucrative out there. Enter Elevest Capital's Fund 69—a testament...